A Multicenter Analysis of Immune Checkpoint Inhibitors as Adjuvant Therapy Following Treatment of Isolated Brain Metastasis
Open Access
- 8 December 2020
- journal article
- research article
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 26 (3) , e505-e507
Abstract
Background: The objective of this work was to characterize outcomes of patients with isolated brain metastases managed with local therapy followed by immune checkpoint inhibitor (ICI) therapy. Materials and Methods: Patients from four medical centers were included if they presented with isolated brain metastases treated with local therapy and received adjuvant treatment with ICIs. Results: Eleven patients with median size of largest brain metastasis of 3.9 cm, treated with surgical resection (n = 8) and/or stereotactic radiosurgery (SRS; n = 6), were included. Ipilimumab/nivolumab was the adjuvant ICI used in four patients, of whom one recurred (25%) and none died, compared with three of seven (43%) who recurred and two of seven (29%) who died following adjuvant treatment with ICI monotherapy. All recurrences were intracranial. Conclusion: Patients with isolated brain metastases treated with surgery or SRS appeared to benefit from adjuvant ICI therapy, particularly with combination therapy. Recurrences in this setting appear to largely occur intracranially.Keywords
Funding Information
- American Cancer Society (Institutional Research Grant)
- National Comprehensive Cancer Network (Young Investigators Award)
- National Institutes of Health (K23 CA204726, R01CA227481)
This publication has 10 references indexed in Scilit:
- Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trialThe Lancet, 2020
- Incidence, features and management of radionecrosis in melanoma patients treated with cerebral radiotherapy and anti‐PD‐1 antibodiesPigment Cell & Melanoma Research, 2019
- Long-Term Survival of Patients With Melanoma With Active Brain Metastases Treated With Pembrolizumab on a Phase II TrialJournal of Clinical Oncology, 2019
- Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the BrainNew England Journal of Medicine, 2018
- Adjuvant Pembrolizumab versus Placebo in Resected Stage III MelanomaNew England Journal of Medicine, 2018
- Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 studyThe Lancet Oncology, 2018
- Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV MelanomaNew England Journal of Medicine, 2017
- Clinical outcomes of melanoma brain metastases treated with stereotactic radiosurgery and anti-PD-1 therapy, anti-CTLA-4 therapy, BRAF/MEK inhibitors, BRAF inhibitor, or conventional chemotherapyAnnals of Oncology, 2016
- Nivolumab in Previously Untreated Melanoma withoutBRAFMutationNew England Journal of Medicine, 2015
- Improved Overall Survival in Melanoma with Combined Dabrafenib and TrametinibNew England Journal of Medicine, 2015